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Introduction
Cancer- related fatigue is one of the most prevalent symp-
tom [1] in breast cancer patients. Cancer- related fatigue 
is defined as a complex subjective state characterized by 
a reduction in physical and mental abilities affecting cancer 
patients, from time of diagnosis and throughout treat-
ment, as well as survivors [2]. One of the tools for meas-
uring cancer- related fatigue is the Multidimensional Fatigue 
Inventory (MFI- 20) [3]. Several studies have explored 
fatigue change in breast cancer patients during treatments 
using the MFI- 20 [4–6]. These studies showed heteroge-
neous results with different patterns of increase, decrease, 
or stability in fatigue over time. Moreover, all these studies 
assumed so- called longitudinal measurement invariance 
[7] assuming that patients respond consistently on patient- 
reported outcomes (PRO) and that they are directly com-
parable over time, which can be questioned. Indeed, in 
breast cancer, it is likely that patients might regularly 
adapt to their illness and, as a consequence, might give 
different answers to the questionnaires over time, not 
only because their fatigue has changed, but also because 
ORIGINAL RESEARCH
Identifying patterns of adaptation in breast cancer patients 
with cancer- related fatigue using response shift analyses at 
subgroup level
Maxime Salmon1, Myriam Blanchin1, Christine Rotonda2,3, Francis Guillemin2,4 & Véronique Sébille1,5
1University of Nantes, University of Tours, INSERM, SPHERE U1246, Nantes, France
2University of Lorraine, University of Paris Descartes, EA 4360 APEMAC, Nancy, France
3Center Pierre Janet, University of Lorraine, EA4630 APEMAC/EPSAM, Metz, France
4INSERM CIC, 1433 Clinical eidemiology – Nancy University Hospital, Nancy, France
5Department of Biostatistics, Nantes University Hospital, Nantes, France
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Breast cancer, fatigue, patient-reported 
outcome measures, response-shift, structural 
equation modeling
Correspondence
Véronique Sébille, University of Nantes, 
University of Tours, INSERM, SPHERE U1246, 
Nantes, France. Tel: +33 (0)253009120;  
E-mail: veronique.sebille@univ-nantes.fr
Funding Informaiton
This work was supported by the Institut 
National du Cancer [grant number 
INCA_6931].
Received: 7 June 2017; Revised: 2 September 
2017; Accepted: 5 September 2017
Cancer Medicine 2017; 6(11):2562–2575
doi: 10.1002/cam4.1219
Abstract
Fatigue is the most prevalent symptom in breast cancer. It might be perceived 
differently among patients over time as a consequence of the differing patients’ 
adaptation and psychological adjustment to their cancer experience which can 
be related to response shift (RS). RS analyses can provide important insights 
on patients’ adaptation to cancer but it is usually assumed that RS occurs in 
the same way in all individuals which is unrealistic. This study aimed to identify 
patients’ subgroups in which different RS effects on self- reported fatigue could 
occur over time using a combination of methods for manifest and latent vari-
ables. The FATSEIN study comprised 466 breast cancer patients followed over 
a 2- year period. Fatigue was measured with the Multidimensional Fatigue In-
ventory questionnaire (MFI- 20) during 10 visits. A novel combination of Mixed 
Models, Growth Mixture Modeling, and Structural Equation Modeling was used 
to assess the occurrence of RS in fatigue changes to identify subgroups display-
ing different RS patterns over time. An increase in fatigue was evidenced over 
the 8- month follow- up, followed by a decrease between the 8- and 24- month. 
Four latent classes of patients were identified. Different RS patterns were detected 
in all latent classes between the inclusion and 8 months (last cycle of chemo-
therapy). No RS was evidenced between 8- and 24- month. Several RS effects 
were evidenced in different groups of patients. Women seemed to adapt dif-
ferently to their treatment and breast cancer experience possibly indicating 
differing needs for medical/psychological support.
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their perception of what fatigue means to them has changed. 
This phenomenon is often referred to as response shift 
(RS) [8] which has been hypothesized to have three dif-
ferent manifestations: recalibration (change in the patient’s 
internal standards of measurements), reprioritization 
(change in the patient’s values), and reconceptualization 
(change in the patient’s definition of the measured 
concept).
In case of RS, it might be problematic or even impos-
sible to distinguish, without appropriate methodology, 
change in fatigue from RS effects. The assessment of 
therapeutic interventions can then lead to inappropriate 
results, poor power to detect intervention effects and 
erroneous conclusions. At the same time, one can highlight 
the therapeutic importance of RS itself, allowing a better 
understanding of how patients adjust to their illness. 
Indeed, RS could be one of the goals of therapy in help-
ing patients to cope with their disease and to live with 
it. Therefore, RS can be simultaneously viewed as meas-
urement bias as well as an indication of a possible thera-
peutic benefit coming from some form of psychological 
adaptation or adjustment. Thus, it is important to assess 
the change experienced by patients by taking into account 
RS if appropriate, but also to detect this phenomenon 
and quantify it in a reliable and unbiased manner.
Most approaches proposed for RS detection and adjust-
ment in the appraisal of change in PRO over time are 
performed at the sample- level such as Structural Equation 
Modeling (SEM) [9] or Item Response Theory (IRT) [10]. 
Hence, RS is considered on the overall sample of patients 
regardless of individual characteristics. It is thus assumed 
that the majority of the sample has been affected by the 
same change in the perception of fatigue over time. 
Nevertheless, we can suspect that among a sample, only 
some individuals might be affected by RS and different 
types of RS might affect different individuals to different 
extent. An alternative approach has been proposed [11] 
allowing the detection of RS and its possible time of 
occurrence at a subgroup level, however, it does not allow 
for the identification of the form of RS that might have 
occurred (recalibration, reprioritization, reconceptualiza-
tion). For this purpose, this method could be comple-
mented with other approaches such as SEM using Oort’s 
procedure [9] for identifying the different forms of RS. 
However, to the best of our knowledge, it has never been 
done despite its potential for detailed RS identification 
at a subgroup level.
Our objective was to identify the possible different pat-
terns of RS in a sample of breast cancer patients. A 
combination of methods was proposed to assess the occur-
rence of RS in the evolution of self- reported fatigue over 
time and to identify subgroups of patients regarding dif-
ferent patterns of two RS processes (recalibration, 
reprioritization) to disentangle the contributions of RS 
effects and latent fatigue (unobserved fatigue level of 
patients) changes to the observed change.
Method
Data collection
The FATSEIN study [12] included breast cancer patients 
recruited in the cancer care centers of Nancy, Dijon, and 
Strasbourg in France and followed up for 24 months after 
surgery. Informed consent was obtained from all individu-
als participants included in the study. Eligibility criteria 
included women newly diagnosed with invasive breast 
cancer, undergoing breast surgery as primary treatment, 
age ≥18 years, without history of other cancer, no other 
major disabling medical or psychiatric conditions, no 
previous chemotherapy or radiotherapy, no metastases, 
and no inflammatory breast cancer. The study has been 
approved by the institutional review board and is regis-
tered at www.clinicaltrials.gov (NTC01064427).
Patients were recruited for a 2 year- follow- up including 
10 visits (Appendix 1). Socio- demographic and medical 
data were collected before surgery. Cancer- related fatigue 
was measured with the MFI- 20 [13] over the 10 visits. 
This questionnaire explores four domains of fatigue (physi-
cal or mental fatigue, reduction in activities or motivation) 
and provides a global fatigue score. Higher scores indicate 
more reported fatigue. Patients also completed the QLQ- 
C30 quality of life (QoL) questionnaire [14] and the 
State- Trait Anxiety Inventory (STAI- State) to measure 
transient anxiety [15] over time. The STAI- Trait [15] and 
the LOT (LOT) [16] were completed at inclusion to 
measure enduring levels of trait anxiety and optimism. 
Higher scores for the State- Trait Anxiety Inventory and 
for the LOT indicate more reported anxiety and optimism, 
respectively.
Statistical analysis
Several steps were performed (Fig. 1). SAS version 9.4 
and Mplus version 7.2. were used. Two- sided P values<0.05 
were considered statistically significant.
Firstly, the change in global fatigue score of the MFI- 20 
was assessed using a mixed model from which the residu-
als were retained. The final model was selected using an 
ascending strategy where time effect and sociodemographic 
covariates were added according to Wald tests (P < 0.05). 
Since it was expected that chemotherapy treatment could 
modify fatigue change, it was added as a fixed effect, as 
well as its interaction with time. The addition of random 
effects on the intercept or the slope was assessed using a 
likelihood ratio test (LRT). The studentized residuals were 
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obtained by dividing the conditional residuals of the mixed 
model by the estimate of their standard deviation; they 
were subsequently centered by removing their mean for 
each subject. This allowed pulling out the effect of a poor 
fit (high or low residuals). Following Mayo et al. [11]., 
the change in residuals quantifying the difference between 
the observed global fatigue and what would have been 
predicted based on all the variables significantly associated 
with fatigue change was considered as an indicator of RS. 
It was assumed that the fluctuation in a patient’s residuals 
over time might be due to RS. Hence, we considered that 
a subject with centered residuals close to zero for all meas-
urement occasions did not experience RS.
Secondly, different latent classes (LC) of homogeneous 
centered residuals growth trajectories were identified as 
well as the time points where RS was expected to occur 
using Growth Mixture Models (GMM) [17]. A categorical 
latent variable representing the different classes was 
included in the model and LC membership was inferred 
from data. The growth parameters (intercept and slope) 
could be different in each LC. The selection of the best 
fitting GMM and of the number of classes relied on the 
sample size–adjusted Bayesian information criteria (SABIC) 
[18]. We constrained the minimum sample size to be at 
least 10% of the total sample size in all LC to enhance 
SEM convergence while keeping a maximum of different 
possible clinically meaningful trajectories. When the num-
ber of LC was identified, posterior probabilities of LC 
membership were estimated for all patients. Each patient 
was assigned to the LC with the highest posterior prob-
ability [17]. Lastly, the time points between which RS 
could be experienced by patients were determined using 
the highest range of the residuals in each LC, and the 
treatment history that could have triggered RS. The dis-
tribution of the socio- demographic and medical variables, 
QoL, optimism and anxiety scores measured at inclusion 
and over time were compared between the LC using 
analysis of variance (ANOVA), chi- square tests, and mixed 
models.
Thirdly, the occurrence of reprioritization, uniform/
non- uniform recalibration RS in each of these LC and 
its effect on observed fatigue changes measured by the 
scores of the four domains of the MFI- 20 between the 
previously selected time points were assessed using SEM 
[9] following a four- step method which is briefly described. 
This procedure was performed on the overall sample and 
in each LC allowing estimating three components of 
changes: observed changes, RS and latent change contri-
butions to the observed change. Mathematical formulation 
of the SEM model, models’ identification constraints, and 
operationalization of RS (RS parameters) appear in 
Appendix 2.
Figure 1. Sequential steps for response shift (RS) analyses.
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Step 1
A “measurement model” (model 1) is first estimated 
(Fig. 2) with no across measurement constraints for RS 
parameters: factor loadings (reprioritization RS), intercepts 
(uniform recalibration RS) or residual variances (non- 
uniform recalibration RS). The common factor is measured 
at two measurement occasions (Fatigue(1), Fatigue(2)); it 
is assumed to explain the relationships between the observed 
variables (domain scores at time t: physical fatigue (p.f(t)), 
mental fatigue (m.f(t)), reduction in activities (r.a(t)), reduc-
tion in motivation (r.m(t))). The model fit was considered 
acceptable if root mean square error of approximation 
index (RMSEA) was <0.08, comparative fit index 
(CFI) > 0.95, Tucker- Lewis Index (TLI) > 0.95 and stand-
ardized root mean square residual index (SRMR) ≤0.08 
[19]; across time correlations between domain scores were 
possibly added to reach satisfactory fit.
Step 2
A “no RS model” (model 2) is estimated with across meas-
urement constraints for all RS parameters. An overall test 
for RS is performed with a LRT (model 1 vs. model 2). If 
the LRT is significant, RS is assumed. In that case, the types 
of RS are identified and estimated in step 3. Otherwise, overall 
RS has not been detected. In this case, the most parsimoni-
ous model 2 is kept, step 3 is skipped to go to step 4.
Step 3
Starting with model 2, step- by- step inspection of RS param-
eters that significantly improve model fit gives model 3. 
Across time correlations between residual factors are pos-
sibly added followed by residual factor correlations at the 
same measurement occasion, until satisfactory fit is reached.
Step 4
This final step allows estimating and testing the latent 
change in fatigue (model 4). The effect sizes [9] of the 
latent change and of RS are computed as shown in 
Appendix 2. Of note, non- uniform recalibration is related 
to a change in residual variances that does not affect the 
mean observed change; it may indicate that the change 
in the scaling of the responses is not in the same direc-
tion or that it differs between patients.
Figure 2. Measurement model in step 1. 휋 (t)
d
, 휏 (t)
d
 Δ(t)
d
: unobserved residuals variances, intercepts, factor loadings of domain d at time t, respectively. 
Φ(1,2): across occasion covariance of the latent construct of fatigue.
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Results
Sample characteristics
A sample of 466 women was recruited. Their mean age 
was 57 years, they were usually married (75 %) with 1 
or 2 children (63 %) and living with their families (80 %). 
Women were mostly affected by a stage I and II cancer 
(84%). Most of them had a lumpectomy (78 %), a sen-
tinel node surgery (50 %), and a neo- adjuvant treatment 
based on radiotherapy with or without chemotherapy and 
hormone therapy.
Change in global fatigue, in residuals, and 
identification of the latent classes
The variables significantly associated with fatigue change 
were time, chemotherapy and marital status. Global fatigue 
significantly changed over time (P < 0.001). It increased 
from baseline to 4- month, remained stable between 
4- and 8- month and decreased during the last months 
of follow- up. At 4- and 8- months follow- up, married 
women treated with chemotherapy reported more fatigue 
than married women without chemotherapy on average. 
At the last follow- up, the mean global fatigue scores were 
close whatever the treatment group.
A model with four LC (LC1- LC4) displayed the lowest 
SABIC and satisfied the required minimum sample size in 
each LC. Figure 3 shows the estimated means of the centered 
residuals at each time of measurement for the four LC. 
There were 154 (33%) women in LC1, 61 (13%) in LC2, 
118 (25%) in LC3, and 112 (24%) in LC4. Twenty- one 
patients could not be assigned to a LC because of missing 
data on marital status (n = 9), treatment group (n = 9) or 
both (n = 3). At inclusion (Table 1), the mean ages were 
significantly different (P < 0.05) between LC1 (58.3 years) 
and LC4 (54.4 years), and there were more patients without 
chemotherapy in LC1 (n = 83, 54%) as compared to other 
LC especially LC4 (n = 42, 38%). The mean enduring levels 
of anxiety measured by the STAI- Trait were not significantly 
different between the LC (P = 0.33) but the optimism scores 
of the LOT were lower in LC3 as compared to LC2 (P < 0.05). 
During follow- up, change in the observed transient anxiety 
levels measured by the STAI- State was not significantly dif-
ferent between the LC (P = 0.16). In contrast, the observed 
changes in all the functional domains of the QoL question-
naire QLQ- C30 were significantly different over time between 
the LC (Fig. 4). The observed mean scores in LC2 were 
usually higher compared to the other LC (especially LC4) 
and quite stable over time for the following dimensions: 
General Health (GH, Fig. 4A), Physical Functioning (PH, 
Fig. 4B), Cognitive Functioning (CF, Fig. 4D), Social 
Functioning (SF, Fig. 4E), Role Functioning (RF, Fig. 4F). 
Conversely, for these dimensions, in LC4, the observed mean 
scores fluctuated more and usually decreased from baseline 
to 8- month and subsequently increased until the end of 
follow- up either reaching their initial baseline level (for the 
GH dimension) or remaining below it (on average −8 points 
for SF, −7 for CF, −10 for PF and RF at 24- month as 
compared to baseline). Moreover, the difference between the 
observed mean scores in LC4 and LC2 (LC4 minus LC2) 
ranged from −3 points at baseline to −22 at 8- month, and 
was −5 points at the end of follow- up on average. In latent 
classes LC1 and LC3, the mean scores change in the GH, 
PH, CF, SF, and RF dimensions were usually close to one 
another. In contrast, for the Emotional Functioning (EF, 
Fig. 4C) dimension, at baseline, the observed mean scores 
were lower in LC3 as compared to the other LC (−14 points, 
−10, and −8 on average as compared to LC2, LC1, and 
LC4, respectively, P < 0.05). The mean scores subsequently 
increased in LC2 and LC3 until the end of follow- up (+16 
and +20 points in LC2 and LC3 on average, respectively) 
but remained lower in LC3 as compared to LC2 (−9 points 
on average) at 24- month.
Based on the mean trajectories of the centered residuals 
in the different LC (Fig. 3), and taking into account the 
end of the chemotherapy treatment (8- month after sur-
gery), baseline and 8- month, and 8- and 24- month after 
Figure 3. Evolution over time of the observed means of the centred residuals in each latent class.
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surgery were considered as the two time periods where 
RS could have occurred.
Response shift analyses
Baseline to 8 months after surgery
Appendix 3 shows how the SEM fitted during the four- 
step method proposed by Oort [9] (from model 1 to final 
model 4). In each LC, the fit of model 4 was satisfactory, 
all the fit indices were acceptable: RMSEA < 0.08, 
CFI > 0.95, TLI > 0.95, and SRMR ≤0.08. Table 2 shows 
the results of the RS analyses using SEM [9] in each latent 
class and in the whole sample. The types of RS that have 
been identified in the different latent classes and in the 
whole sample are shown as well as the effect sizes of the 
contributions of RS and latent changes to the observed 
changes (assuming that RS contribution + latent change 
contribution ≅ observed changes). Several forms of RS 
were identified in each LC and in the whole sample. In 
LC1, reprioritization (decrease of the factor loadings) was 
detected. Thus, 8 months after surgery, women considered 
physical fatigue as less important to characterize the latent 
construct of fatigue as compared to baseline. Uniform 
recalibration in physical fatigue and mental fatigue was 
also detected (decrease in the intercepts). It indicated that 
women tended to score lower on the items of physical 
or mental fatigue at 8 months compared to baseline despite 
an increase in the mean level of latent fatigue (effect 
sizes = 0.48 and 0.51 for latent changes in physical and 
Table 1. Socio- demographic and medical characteristics of study population at baseline in the whole sample and in each latent class.
Characteristics
Whole sample 
N = 466
Number of 
missing values LC1 (N = 154) LC2 (N = 61) LC3 (N = 118) LC4 (N = 112) P- value
Socio-demographic
Age 57.0 (10.4) 9 58.3 (10.8) 58.3 (11.0) 56.9 (9.6) 54.4 (10.1) 0.0181
Marital status 12
Single 34 (8%) 15 (10%) 7 (12%) 5 (4%) 6 (5%)
Widowed 36 (8%) 15 (10%) 5 (8%) 9 (8%) 5 (5%) 0.414
Divorced 45 (10%) 17 (11%) 4 (7%) 13 (11%) 11 (10%)
Married 339 (75%) 107 (70%) 45 (74%) 91 (77%) 90 (80%)
Number of children 8
None 48 (11%) 14 (9%) 6 (10%) 15 (13%) 10 (9%)
1 or 2 287 (63 %) 92 (60%) 39 (65%) 74 (63%) 73 (66%) 0.813
>2 123 (27 %) 48 (31%) 15 (25%) 29 (25%) 28 (25%)
Educational level 58
End of the 
compulsory school
213 (52 %) 72 (52%) 30 (59%) 57 (53%) 47 (48%)
High school degree 85 (21 %) 27 (19%) 11 (22%) 19 (18%) 27 (28%) 0.516
Higher education 110 (27 %) 40 (29%) 10 (20%) 32 (30%) 24 (25%)
Employment status 9
Employed 274 (60 %) 83 (54%) 34 (56%) 67 (57%) 80 (73%)
Unemployed 40 (9 %) 18 (12%) 4 (7%) 12 (10%) 5 (5%) 0.053
Pensioner 143 (31 %) 52 (34%) 23 (38%) 39 (33%) 25 (23%)
Medical
Type of breast surgery 3
Lumpectomy 362 (78 %) 125 (81%) 46 (75%) 89 (75%) 90 (80%) 0.596
Mastectomy 101 (22 %) 29 (19%) 15 (25%) 29 (25%) 22 (20%)
Stage of cancer 18
Stage I 239 (53 %) 87 (58%) 28 (47%) 55 (47%) 59 (54%)
Stage II 180 (40 %) 54 (36%) 29 (48%) 53 (46%) 42 (38%) 0.490
Stage III 29 (7 %) 8 (5%) 3 (5%) 8 (7%) 9 (8%)
Chemotherapy 12
No Chemotherapy 206 (45 %) 83 (54%) 29 (48%) 48 (41%) 42 (38%) 0.037
Chemotherapy 248 (55 %) 71 (46%) 32 (53%) 70 (59%) 70 (63%)
PRO measures
Trait anxiety STAI-Trait 47.9 (4.5) 40 47.7 (4.4) 47.2 (4.7) 48.3 (4.6) 48.2 (4.4) 0.333
Optimism LOT 19.8 (5.4) 77 20.4 (4.9) 21.1 (5.3) 18.7 (5.4) 19.6 (5.8) 0.0352
LC1: latent class 1, LC2: latent class 2, LC3: latent class 3, LC4: latent class 4. PRO: Patient- Reported Outcomes; Mean (standard deviation) for con-
tinuous data, frequency (percentage) for categorical data;
1ANOVA, post hoc tests significant between LC1 and LC4;
2ANOVA, post hoc tests significant between LC2 and LC3; categorical data were compared with chi- square tests.
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mental fatigue, respectively). The effect sizes of the observed 
changes were thus both reduced by RS effects (effect 
sizes = 0.17 and 0.12 for observed changes in physical 
and mental fatigue, respectively). Finally, a decrease in the 
residual variance of the mental fatigue at 8 months was 
evidenced (non- uniform recalibration).
In LC2, reprioritization was evidenced in physical fatigue 
(increase in the factor loadings); this domain was more 
indicative in the construct of latent fatigue at 8 months 
of follow- up as compared to baseline. Effect sizes of 
observed changes were thus higher than those of latent 
changes. Uniform recalibration in mental fatigue was also 
observed (decrease in the intercepts). The observed mental 
fatigue effect size was thus reduced by RS. Lastly, 
non- uniform recalibration was evidenced with an increase 
in the residual variance of the domain “Motivation reduc-
tion” at 8 months.
In LC3 and LC4, decreases in the factor loadings of 
the physical fatigue and in the intercepts of the mental 
fatigue were observed. Moreover, in LC4, non- uniform 
recalibration occurred (increase in the residuals variances 
of the domain “Motivation reduction”). In these LC, both 
observed mental and physical fatigue changes were reduced 
by RS effects. Thus, in all LC, observed changes in physi-
cal and mental fatigue underestimated changes in latent 
fatigue, except for physical fatigue in LC2.
Furthermore, in LC1 and LC4, at 8- month of follow-
 up, reprioritization RS effects lead all factor loadings to 
Figure 4. Change in the scores of the functional domains of the QLQ- C30 quality of life questionnaire over the follow- up.
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become closer to each other meaning that women gave 
the same importance to all domains of fatigue at follow-
 up. The parameters estimates of model 4 for LC1 are 
shown in Figure 5. Parameters separated by a slash rep-
resent first and second measurement occasion estimates; 
all other parameters were equal across measurement occa-
sions. Three types of RS were detected indicated in bold: 
reprioritization in physical fatigue (decrease in factor 
loadings), uniform recalibration in mental and physical 
fatigue (decrease in the intercepts) and non- uniform 
recalibration in mental fatigue (decrease in the residual 
variances).
In summary, the changes in the mean level of latent 
fatigue in all dimensions increased in all LC (all the 
effect sizes were positive). However, it seems that LC1 
corresponded to the patients with the lowest increase 
in fatigue (effect sizes ranging from 0.42 for “reduction 
in motivation” to 0.51 for “mental fatigue”) as compared 
to the other LC (effect sizes ranging from 0.50 for 
“reduction in motivation” in LC2 to 0.74 for “mental 
fatigue” in LC3). Moreover, it also seems that the con-
tribution of RS was more important (in absolute value) 
in LC1 as compared to the other LC for “physical 
fatigue” (−0.32 in LC1 and ranging from −0.11 to +0.11 
in the other LC) and “mental fatigue” (−0.38 in LC1 
and ranging from −0.34 to −0.26 in the other LC). 
The only positive effect size of RS contribution was 
observed in LC2 for “physical fatigue” which became 
more indicative of the fatigue construct (reprioritization) 
but it was counterbalanced by uniform recalibration in 
“mental fatigue” which reduced the observed change in 
this dimension (0.27) which was lower than the observed 
changes in LC3 (0.40) and LC4 (0.38). Finally, uniform 
recalibration in “mental fatigue” was the lowest in LC4 
in absolute value (RS contribution = −0.26) as compared 
to the other LC (RS contribution ranging from −0.34 
to −0.38).
Lastly, in the whole sample, reprioritization was detected 
for physical fatigue (decrease in the factor loadings), uni-
form recalibration for mental fatigue (decrease in the inter-
cepts) and reduction in activities (increase in the intercepts). 
Non- uniform recalibration was also detected for mental 
fatigue and reduction in motivation with a decrease and 
an increase in the residual variances, respectively.
Table 2. Response shift analyses using Structural Equation Modeling in the four latent classes and the whole sample between baseline and 8 months 
after surgery.
Latent class Response shift Effect size
R UR NUR Observed changes RS contribution
Latent change 
contribution
LC1
Physical fatigue x x 0.17 −0.32 0.48
Mental fatigue x x 0.12 −0.38 0.51
Activity reduction 0.44 0.44
Motivation reduction 0.42 0.42
LC2
Physical fatigue x 0.72 0.11 0.61
Mental fatigue x 0.27 −0.34 0.61
Activity reduction 0.55 0.55
Motivation reduction x 0.50 0.50
LC3
Physical fatigue x 0.53 −0.11 0.64
Mental fatigue x 0.40 −0.34 0.74
Activity reduction 0.61 0.61
Motivation reduction 0.55 0.55
LC4
Physical fatigue x 0.36 −0.23 0.58
Mental fatigue x 0.38 −0.26 0.63
Activity reduction 0.54 0.54
Motivation reduction x 0.63 0.63
Whole sample
Physical fatigue x 0.41 −0.08 0.49
Mental fatigue x x 0.27 −0.25 0.52
Activity reduction x 0.59 0.14 0.45
Motivation reduction x 0.43 0.43
LC1, latent class1; LC2, latent class 2; LC3, latent class 3; LC4, latent class 4; R: reprioritization, UR: uniform recalibration, NUR, non- uniform 
recalibration, RS: response shift.
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Eight months after surgery to the 
end of the follow- up
The test of overall RS was not significant for all LC and 
the whole sample; hence RS was not evidenced between 
these two time points. The latent and observed changes 
were therefore the same. A decrease in fatigue was observed 
with the following effect sizes: −0.19, −0.03, −0.41, −0.58, 
and −0.29 in LC1, LC2, LC3, LC4, and in the whole 
sample, respectively.
Discussion
Different patterns of RS effects on self- reported cancer- 
related fatigue were identified in subgroups of breast cancer 
patients. Four LC were identified where different forms 
of RS and effect sizes were evidenced between baseline 
and 8 months after surgery (1 month after the last cycle 
of chemotherapy). In contrast, no RS was evidenced 
between 8 and 24 months after surgery. In all LC and 
in the whole sample an increase in the latent fatigue was 
evidenced over the 8- month follow- up, followed by a 
decrease between 8- and 24- month. During the first time 
period (from baseline to 8 months), the LC can be ten-
tatively characterized as follows. LC1 corresponds to the 
oldest patients receiving less chemotherapy and showing 
the lowest increase in latent fatigue and the highest RS 
effects. In contrast, LC4 corresponds to the youngest 
patients receiving more chemotherapy, showing the lowest 
recalibration RS effects, and usually the poorest QoL 
between 4 and 8 months. Other studies using latent class 
analysis to identify subgroups of cancer patients with dif-
fering symptom experiences have also reported that, as 
compared to older patients, younger patients often display 
the highest levels of symptoms and the lowest QoL levels 
which could be explained by the fact that older patients 
might receive less chemotherapy and that they could be 
more prone to RS [20, 21]. However, the reverse has 
also been reported regarding the association between RS 
and younger age [22] and more research is needed on 
this topic. LC2 was the smallest latent class and comprised 
patients with the same age mean as those in LC1, the 
highest mean optimism score (P < 0.05 as compared to 
LC3), usually the highest levels of QoL over the follow-
 up and for whom reprioritization RS went in an opposite 
direction as compared to the other LC indicating that 
“physical fatigue” became more indicative of the fatigue 
construct at 8- month compared to baseline but with 
recalibration RS in “mental fatigue” also being evidenced 
as in the other LC. LC3 comprised patients with the 
highest increase in latent fatigue (“physical,” “mental 
fatigue,” and “activity reduction”), the same recalibration 
RS effects in “mental” fatigue” as compared to LC2 but 
with a lower mean optimism score and a lower QoL at 
baseline regarding emotional functioning as compared to 
the other LC. During the second time period (from 8 to 
24 months), a decrease in fatigue was observed in all LC 
but it was more marked in LC4 (effect size = −0.58) as 
compared to the other LC where the effects sizes ranged 
from −0.03 in LC2 to −0.41 in LC3. Hence, during this 
time period after the end of treatments, patients in LC4 
who were younger seem to have a better ability to recover 
from fatigue.
During the first time period, in all LC and the whole 
sample, uniform recalibration RS was evidenced in mental 
fatigue. This led women to score lower 8 months after 
surgery as compared to baseline on this domain, despite 
a mean increase in latent fatigue. Uniform recalibration 
was also detected for physical fatigue in the same direc-
tion but only in LC1. Such uniform recalibration RS could 
indicate some form of psychological adjustment such as 
adaptation [23] to the mental and physical fatigue 
Figure 5. Parameters estimates of model 4 in latent class 1 between baseline and 8 months after surgery.
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experienced by women over time leading them to score 
lower on these domains after the last cycle of chemo-
therapy despite an increasing level of fatigue. Recalibration 
RS in fatigue was similarly observed in other studies in 
breast cancer patients where the then- test approach [22, 
24] was mostly used. This approach uses a retrospective 
(then- test) self- assessment of the pretest level initially 
measured at baseline along with a posttest assessment 
(e.g., 8 months after surgery). In this approach, the dif-
ferences between pretest and then- test assessments and 
between posttest and then- test assessments are assumed 
to represent recalibration RS and latent change, respec-
tively. Due to its simplicity, this approach is still used 
but has some pitfalls such as requiring an additional 
questionnaire, detecting only recalibration RS, being prone 
to recall bias [25, 26]. Thus, SEM [9] or other approaches 
such as IRT [10] are sometimes now more often 
preferred.
In the 1st, 3rd and 4th LC, reprioritization RS was 
detected in the physical fatigue domain which became 
less indicative of the latent construct of fatigue at month 
8 compared to baseline whereas it went in the opposite 
direction in LC2. Reprioritization RS was also observed 
in other studies focusing on QoL in prostate and breast 
cancer patients [27, 28] where change in priorities and 
importance given to social or physical domains were evi-
denced over time as being more or less indicative of QoL 
or subjective well- being.
In all these studies RS was investigated at a sample 
level, assuming that this phenomenon is experienced in 
the same way for the majority of the sample which might 
not be very realistic. One can indeed expect that there 
is significant variability between patients due to different 
experiences and personality traits and that RS, often related 
to patients’ adaptation to illness might not have similar 
manifestations in all individuals. To date, quite a few 
studies examined RS at more individual level aside from 
Mayo et al. [11]. who used mixed models and GMM in 
a sample of stroke patients but without distinguishing 
the different forms of RS and Blanchin et al. [29]. who 
used IRT and Guttman errors [30] to detect discrepancies 
in respondent’s answers compared to some expected 
response pattern (e.g. no RS) in a sample of hospitalized 
chronically ill patients. In the latter, RS was investigated 
at item- level within a single dimension of the SF- 36 ques-
tionnaire (General Health).
In our study, different forms of RS could be assessed 
at a sub- sample level on several dimensions of fatigue. 
Patients in LC1 seemed to be more prone to recalibration 
RS in physical and mental fatigue which could be associ-
ated with a better adaptation to illness and to its symp-
toms. This might related to the fact that these patients 
were older and received less chemotherapy. In contrast 
patients in LC4 who were younger and received more 
chemotherapy displayed the lowest recalibration RS and 
poor QoL. Some limitations and paths for future research 
can be outlined. The change in residuals was considered 
as an indicator of RS [11], but residuals could change 
over time for other reasons such as poor model fit. 
Nevertheless, the residuals of the mixed model were close 
to zero at each time so the model had a good fit 
(Appendix 4). The choice of the number of LC relied 
on the SABIC that has been shown to be more efficient 
than several other criteria such as AIC and BIC to detect 
the true number of LC in simulation studies [18]. Yet, 
women were assigned to a LC according to their highest 
posterior probability. The uncertainty of classification was 
therefore not taken into account [31]. There have been 
some recommendations in the mixture modeling literature 
to deal with this issue [32, 33] but their feasibility and 
performance are unknown to date in SEM for RS analyses. 
All estimation methods (ML and REML) assumed ignor-
able missing data [34]. In case of non- ignorable missing 
data, the probability of missingness depends on unobserved 
data (patients might be too tired to fill in the fatigue 
questionnaire) which can lead to biased estimates of RS 
and change in PRO [35]. Although the underlying missing 
data mechanism is uncertain, in our sample, the com-
parison between patients who had missing data or not 
did not reveal any significant differences on covariates 
distributions.
The results of our study showed that RS was experienced 
in all LC and in the whole sample but with different 
forms and extent. Moreover, women also experienced strong 
tiredness and probably had to adapt to this situation which 
might be related to the uniform recalibration RS effects 
that were evidenced especially in older patients receiving 
less chemotherapy. Furthermore, in all LC, if RS had not 
been taken into account, observed changes in physical and 
mental fatigue would have underestimated changes in latent 
fatigue, except for physical fatigue in LC2. In conclusion, 
this study confirmed that RS can occur in different ways 
within a sample. The proposed approach allows taking 
into account several aspects of RS by distinguishing several 
groups of women who might have adapted differently to 
their treatment and illness possibly indicating differing 
needs for medical/psychological support. Special attention 
might be given to younger patients with more chemo-
therapy treatment who might have a poorer fatigue experi-
ence and QoL during therapy and could benefit from 
psychological support helping them to cope and to better 
adjust with their symptom experience.
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APPENDIX 1
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Flowchart of the treatments timeline. CT: chemotherapy; CT #: evaluation at the first day of the cycle of chemotherapy 
n°#; RT: evaluation just before the beginning of radiotherapy; End of RT: evaluation during the last week of 
radiotherapy.
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APPENDIX 2
Mathematical formulation of the SEM 
model, models’ identification in the 
different steps, RS parameters, and 
effect sizes
Underlying model
This model is based on SEM. For the ith patient, we can 
write:
Where Wi is the vector of observed domain scores (physi-
cal and mental fatigue, reductions of activities and moti-
vation), τ the matrix of intercepts, Δ the matrix of loading 
factors, ξi the vector of unobserved common factor (the 
latent construct fatigue), πi the vector of unobserved 
residuals factors.
In SEM, models are usually written as mean and covari-
ance patterns as follows:
where a is the vector of common factor means.
The covariance of the fatigue domains can be written 
as
where Φ is the covariance matrix of the unobserved com-
mon factor (Φ=Cov
(
휉
(1), 휉(2)
)
), and Ω the covariances 
matrix of the unobserved residual factors 
(Ω=Cov
(
휋
(1),휋(2)
)
 at the two measurement occasions (1) 
and (2).
The Δ and τ matrices can be written as:
where τ(1) and τ(2) are the vectors of the intercepts and 
Δ(1) and Δ(2) the two vectors of the factor loadings at 
the two measurement occasions.
The mean and variance structures of the common 
factors are:
where a(1) and a(2) are the means of the two common 
factors (the means of the fatigue), Φ(11) and Φ(22) the 
two variances of the common factors construct at each 
measurement occasions, and Φ(12) and Φ(21) the covari-
ances of the common factors (Φ(12) = Φ(21)).
The matrix of residuals factor variances can be written as
where Ω(11) and Ω(22) are the residual factor variance- 
covariance matrices at two measurement occasions, and 
Ω(12) and Ω(21) are the residual factor variance- covariance 
matrices across occasions. Usually, no correlation is 
assumed between residuals at a given time but they can 
be added to improve model fit.
Identification of the models
In order to identify model 1 in step 1 the means of the 
common factor are set equal to zero, and the variances 
of the common factor to 1, at all measurement occasions. 
All other parameters are freely estimated across time. To 
identify model 2 in step 2, the mean and variance of the 
common factor are constrained to be equal to 0 and 1 
at the first measurement occasion, respectively.
RS parameters
RS is operationalized in the following way where 휋(t)
d
, 휏
(t)
d
,Δ
(t)
d
 
are the unobserved residuals variances, intercepts, factor 
loadings of domain d at time t, respectively. Φ(1,2) is the 
across occasion covariance of the latent construct of fatigue. 
Reprioritization corresponds to Δ(1)
d
≠Δ
(2)
d
 for domain d, 
because a change in factor loadings indicates that a domain 
of fatigue has become less or more indicative of the latent 
fatigue construct during follow- up. Respondents could have 
also changed their interpretation of the response scale op-
tions during follow- up showing recalibration. If this change 
occurs in the same direction and to the same extent for 
all items of a domain, a uniform recalibration is assumed 
and corresponds to 휏 (1)
d
≠ 휏
(2)
d
 If the change occurred in 
different directions or extents, non- uniform recalibration 
is assumed and corresponds to 휋(1)
d
≠휋
(2)
d
Effect sizes
The estimated changes in observed fatigue (?̂?(2)− ?̂?(1)) is 
divided into three components. 
where 𝜏 (2)−𝜏 (1) represents the contribution of the uniform 
recalibration to the observed changes in fatigue, (Δ̂(2)−Δ̂(1))â(2) 
the contribution of the reprioritization, Δ̂(2)× â(2) the con-
tribution of the latent changes with a(2) representing the 
change in the construct of fatigue across time (since a(1)=0). 
The effects size of each component is computed by dividing 
it by the estimated standard deviation of the observed changes √
?̂?
(1,1)+ ?̂?(2,2)−2× ?̂?(1,2) where ?̂?(1,1) and ?̂?(2,2) are the estimated 
variances, and ?̂?(1,2) an estimate of across time covariances 
of the observed change in model 4.
W
i
= 휏+Δ휉
i
+휋
i
Mean(W)=휇= 휏+Δa
Cov(W (1),W (2))=
∑
=Δ
(1)
ΦΔ
(2)
+Ω
Δ=
(
Δ
(1) 0
0 Δ(2)
)
and 휏 =
(
휏
(1)
휏
(2)
)
a=
(
a(1)
a(2)
)
and Φ=
(
Φ
(1,1)
Φ
(2,1)
Φ
(1,2)
Φ
(2,2)
)
Ω=
(
Ω
(1,1)
Ω
(2,1)
Ω
(1,2)
Ω
(2,2)
)
?̂?
(2)
− ?̂?
(1)
= (𝜏
(2)
−𝜏
(1)
)+(Δ̂
(2)
−Δ̂
(1)
)â
(2)
+Δ̂
(2)
× â
(2)
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APPENDIX 3
Fit of the Structural Equation Models in the different latent classes and in the whole sample
Fit index
RMSEA CFI TLI SRMR
LC1 Model 1 0.04 0.99 0.99 0.04
Model 2 0.12 0.91 0.91 0.20
Model 3 0.04 0.99 0.99 0.06
Model 4 = Model 3 0.04 0.99 0.99 0.06
LC2 Model 1 0.10 0.97 0.95 0.06
Model 2 0.16 0.87 0.86 0.04
Model 3 0.08 0.97 0.97 0.08
Model 4 0.07 0.98 0.97 0.08
LC3 Model 1 0.09 0.98 0.96 0.05
Model 2 0.11 0.94 0.94 0.15
Model 3 0.12 0.91 0.91 0.20
Model 4 0.07 0.98 0.97 0.05
LC4 Model 1 0.04 0.99 0.99 0.04
Model 2 0.07 0.97 0.96 0.20
Model 3 0.04 0.99 0.99 0.06
Model 4 = Model 3 0.04 0.99 0.99 0.06
Whole sample Model 1 0.08 0.97 0.96 0.04
Model 2 0.12 0.91 0.91 0.19
Model 3 0.07 0.98 0.97 0.04
Model 4 = Model 3 0.07 0.98 0.97 0.04
LC, latent class; RMSEA, root mean square error of approximation; CFI, comparative fit index, TLI, Tucker- Lewis index; SRMR, standardized root 
mean square residuals.
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Figure: Mean of the centered residuals of the mixed model
